PT - JOURNAL ARTICLE AU - YUKARI BANDO AU - JUNYA FURUKAWA AU - YASUYOSHI OKAMURA AU - TAKUTO HARA AU - TOMOAKI TERAKAWA AU - YUZO NAKANO AU - MASATO FUJISAWA TI - Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma AID - 10.21873/anticanres.15557 DP - 2022 Feb 01 TA - Anticancer Research PG - 973--979 VI - 42 IP - 2 4099 - http://ar.iiarjournals.org/content/42/2/973.short 4100 - http://ar.iiarjournals.org/content/42/2/973.full SO - Anticancer Res2022 Feb 01; 42 AB - Background/Aim: The survival benefit of immune checkpoint inhibitors for non-clear cell renal cell carcinoma (nccRCC) is unclear. Our purpose was to evaluate the real-world survival benefit of ipilimumab plus nivolumab retrospectively. Patients and Methods: We retrospectively reviewed medical records of 33 patients with metastatic nccRCC who received combination therapy with ipilimumab plus nivolumab or monotherapy with a molecular targeted agent as initial systemic therapy. Progression-free survival (PFS), overall survival (OS) and objective response rate were compared between the two groups. Results: Median PFS of each therapy was 3.5 and 4.7 months (p=0.61) and median OS was 19.6 and 10.6 months (p=0.23), respectively. Three patients treated with ipilimumab and nivolumab had a complete response, resulting in an objective response rate of 30.0%, while that for molecular targeted therapy was 4.5% (p=0.04). Conclusion: Ipilimumab plus nivolumab achieved statistically non-significant, but longer overall survival and significantly higher objective response rate.